Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EPS (Weighted Average and Diluted) (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.84 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 102.45% to -$0.84 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.43, a 40.96% increase, with the full-year FY2025 number at -$3.43, up 40.96% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.84 for Q4 2025 at Artiva Biotherapeutics, up from -$0.88 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $34.35 in Q4 2024 to a low of -$22.0 in Q2 2024.
  • A 3-year average of -$3.26 and a median of -$0.88 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 342.18% in 2024; the steepest drop was 156.79% in 2024.
  • Artiva Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$14.18 in 2023, then soared by 342.18% to $34.35 in 2024, then plummeted by 102.45% to -$0.84 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's EPS (Weighted Average and Diluted) are -$0.84 (Q4 2025), -$0.88 (Q3 2025), and -$0.88 (Q2 2025).